Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PER-001 in Diabetic Retinopathy
NCT06003751Phase 2Completed
- Sponsor
- Perfuse Therapeutics
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Polymer-based Nanoparticles, Implantable Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of endonentan in diabetic retinopathy (DR), sponsored by Perfuse Therapeutics. Started Aug 2023; status: completed.
02
Drugs
endonentan
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT06003751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003751.